The company's cash runway into mid-2027 provides time for upcoming clinical data readouts in 2026. Investors should monitor the Q2 2026 data readout for SIM0505 and the second half 2026 update for LNCB74 as key value inflection points. The slight increase in net loss and significant cash burn warrant monitoring of future financing needs.
Price Chart
Executive Summary
NextCure reported its full year 2025 financial results, showing a net loss of $55.8 million, a slight increase from $55.7 million in 2024. The company's cash position decreased to $41.8 million from $68.6 million due to $49.6 million in operating cash outflows, partially offset by $22.3 million in equity proceeds. The company expects its current resources to fund operations into the first half of 2027. Key clinical milestones for its SIM0505 and LNCB74 programs are expected in 2026.
Key Financial Metrics
Key Facts
- Net loss was $55.8 million in 2025 vs. $55.7 million in 2024
- Cash, cash equivalents, and marketable securities decreased to $41.8 million from $68.6 million
- Research and development expenses increased to $44.9 million from $41.5 million
- General and administrative expenses decreased to $12.7 million from $15.7 million
- Cash used in operations was $49.6 million, including $13.5 million in upfront license fees for SIM0505
- Proceeds from equity sales were $22.3 million, including a $21.5 million private placement
- Current resources expected to fund operations into the first half of 2027
- Phase 1 dose escalation data for SIM0505 expected in Q2 2026
- Trial update for LNCB74 expected in second half of 2026
Financial Impact
Cash decreased by $26.8 million to $41.8 million; R&D expenses increased by $3.4 million to $44.9 million; net loss increased slightly to $55.8 million
Risk Factors
- Continued cash burn could necessitate future financing
- Clinical trial results may not meet expectations
- Dependence on successful development of SIM0505 and LNCB74 programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-024121 |
| Document: nxtc-20260305x8k.htm | 0001104659-26-024121 |
| Document: 0001104659-26-024121-index-headers.html | 0001104659-26-024121 |
| Document: 0001104659-26-024121-index.html | 0001104659-26-024121 |
| Document: 0001104659-26-024121.txt | 0001104659-26-024121 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | SC 13G | $5.44 | awaiting T+60 | — | $5.72 (+5.06%) |
Sep 25, 2026 4w ago | 425 | $5.08 | awaiting T+60 | — | $5.72 (+12.50%) |
Sep 25, 2026 4w ago | 8-K | $5.08 | awaiting T+60 | — | $5.72 (+12.50%) |
Aug 10, 2026 11w ago | 425 | $6.73 | awaiting T+60 | — | $5.72 (+15.08%) |
Aug 4, 2026 12w ago | 425 | $5.78 | awaiting T+60 | — | $5.72 (−1.12%) |
Aug 3, 2026 12w ago | Insider Buy | $5.78 | awaiting T+60 | — | $5.72 (−1.12%) |
Jul 29, 2026 12w ago | Insider Buy | $5.03 $4.98 | ▼ −0.99% | ▼ −3.46% | $5.72 (+13.62%) |
Jul 14, 2026 15w ago | 425 / 8-K | $6.58 $6.56 | ▼ −0.30% | ▼ −3.68% | $5.72 (−13.15%) |
Jul 14, 2026 15w ago | 8-K | $6.58 $6.56 | ▲ +0.30% | ▲ +3.68% | $5.72 (+13.15%) |
Jun 1, 2026 21w ago | 8-K | $3.38 $5.91 | ▲ +74.85% | ▲ +73.62% | $5.72 (+69.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers